Tirzepatide has already proven itself highly effective in diabetes and obesity; now it is starting to look like the best bet in metabolic dysfunction-associated steatohepatitis (MASH), too. Improvements in both MASH and liver fibrosis after a year’s treatment with Eli Lilly and Company’s GIP/GLP-1 agonist look competitive with the best MASH therapies on a cross-trial basis.
EASL: Tirzepatide Is The One To Beat In MASH
An important mid-stage trial succeeds, but an odd finding on the fibrosis endpoint will spur close examination of Lilly’s incretin.
More from Clinical Trials
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from R&D
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.